Loading...

Home
ETF
ARVN

ARVN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ARVN News

Major Companies Reporting Earnings Next Week

May 03 2026CNBC

Arvinas and Pfizer Launch VEPPANU for Breast Cancer

May 02 2026NASDAQ.COM

FDA Approves Pfizer and Arvinas Breast Cancer Drug

May 01 2026Newsfilter

FDA Approves First PROTAC Therapy for Breast Cancer

May 01 2026stocktwits

VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era

May 01 2026Newsfilter

FDA Approves Breast Cancer Therapy Developed by Pfizer and Arvinas

May 01 2026seekingalpha

ARVINAS INC AND PFIZER TO CHOOSE THIRD-PARTY PARTNER FOR VEPPANU COMMERCIALIZATION

May 01 2026moomoo

ARVINAS INC - FDA APPROVES BEFORE PDUFA DATE OF JUNE 5, 2026

May 01 2026moomoo

ARVINAS RECEIVES FDA APPROVAL FOR VEPPANU (VEPDEGESTRANT) TO TREAT ESR1M, ER+/HER2- ADVANCED BREAST CANCER

May 01 2026moomoo

FDA GREENLIGHTS VEPDEGESTRANT FOR ADVANCED OR METASTATIC ER-POSITIVE, HER2-NEGATIVE, ESR1-MUTATED BREAST CANCER

May 01 2026moomoo

Arvinas Shares Surge 6.9% on Positive Pipeline Expectations

Apr 02 2026NASDAQ.COM

Insider Buying by Waters and Arvinas Directors

Mar 11 2026NASDAQ.COM

Arvinas, Inc. Q4 2025 Earnings Call Insights

Feb 24 2026seekingalpha

Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline

Feb 24 2026seekingalpha

Arvinas Scheduled to Announce Q4 Earnings on February 24

Feb 23 2026seekingalpha

Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop

Feb 12 2026stocktwits